Genome-scale study ID's hundreds of drug targets for Huntington's

Scientists seeking to develop treatments for Huntington’s disease just got a roadmap that could dramatically speed their discovery process. Researchers have used RNAi technology to identify hundreds of “druggable” molecular targets linked to the toxicity associated with HD. The gene RRAS, involved in cell motility and neuronal development, was among the diverse range of modifiers identified. RRAS was revealed as a potent modulator of HD toxicity in multiple HD models.

Read the whole article on Science Daily

More from Science Daily